A Retrospective Immunohistochemistry Study of the Expression of Glycine/ Serine Pathway Molecules in Solid Tumors


Lead sponsor: National University Hospital, Singapore

Source National University Hospital, Singapore
Brief Summary

The purpose of this study is to determine the expression of molecules involved in the glycine/serine pathway using immunohistochemistry in solid tumors. Archived paraffin-embedded pathological specimens from the Department of Pathology, NUH will be obtained. Tissue microarray (TMA) is a high-throughput method of analysing large numbers of formalin-fixed, paraffin-embedded tumor at a minimal cost and effort. To analyse the expression of molecules of putative relevance to the glycine/serine pathway, (such as PSPH, PSAT1, SHMT1, and GLDC), TMA technology will be utilised as previously reported (Kristiansen, Zhang, Soong). Tissue arrays will be constructed from solid tumors including cancers of the colon/ rectum, lung, breast, cervix, ovary, endometrium, fallopian tube, prostate, kidney, testis, stomach, liver, brain and lymphoma. One hundred cases of each tumor type (subject to availability) will be stained using immunohistochemistry. Patient Identifiers will not be collected. Societal benefit in terms of knowledge gained to improve understanding of cancer. No direct risk to subjects as this is a retrospective study of archived pathological tumour samples.

Overall Status Unknown status
Start Date May 2011
Primary Completion Date June 2014
Study Type Observational
Primary Outcome
Measure Time Frame
Change the expression of molecules of putative relevance to the glycine/serine pathway 5 years
Enrollment 1400

Sampling method: Probability Sample


Inclusion Criteria:

- Patients with solid tumor cancer

Gender: All

Minimum age: 21 Years

Maximum age: N/A

Healthy volunteers: No

Overall Contact

Last name: Ross Soo, MBBS

Phone: +65 6779 5555

Email: [email protected]

facility status contact investigator Nationa University Hospital Ross Soo, MBBS +65 6779 5555 [email protected] Ross Soo, MBBS Principal Investigator
Location Countries


Verification Date

April 2014

Responsible Party

Responsible party type: Sponsor

Has Expanded Access No
Study Design Info

Observational model: Cohort

Time perspective: Retrospective

Source: ClinicalTrials.gov